Alzheimer Disease, Bipolar Disorder, FTD, Schizophrenia
Conditions
Keywords
dementia, biomarker
Brief summary
The validation of biomarkers allowing the discrimination of cognitive and behavioral disorders of psychiatric origin from those of neurodegenerative origin would facilitate diagnosis and improve patient management. Neurofilaments, which are markers of neuronal lysis, appear to be a promising biomarker. In a previous preliminary study, the investigators demonstrated significantly lower concentrations of neurofilaments in CSF of psychiatric patients compared to neurodegenerative diseases. The main objective of this study is to validate the plasma assay of neurofilament light chain as a biomarker for the differential diagnosis of psychiatric or neurodegenerative cognitive impairment. Other biomarkers of interest (Tau, TDP-43, GFAP and UCH-L1) will also be analyzed. A sub-part of this study will also focus on the retrospective analysis of the CSF/Plasma correlations of the different biomarkers mentioned above from tube bottom samples taken in routine care.
Detailed description
One hundred twenty participants will be included in this study * 30 participants suffering from psychiatric disorders (bipolar disorder or schizophrenia) without cognitive impairment * 30 participants suffering from psychiatric disorders (bipolar disorder or schizophrenia) with cognitive impairment * 30 participants with a biological diagnosis of Alzheimer's disease * 30 participants with frontotemporal dementia according to Rascosky's criteria All the participants will perform cognitive, behavioral, and psychiatric evaluation and will be have blood sample taken.
Interventions
DIAGNOSTIC_TESTblood sample taken
Comparaison of Neurofilament light chain serum concentration between the arms
Sponsors
Hôpital le Vinatier
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
Four groups of participants will be recruited: participant with psychiatric condition without cognitive impairment, participants with psychiatric condition with cognitive impairment, participants with biological Alzheimer's disease, and participant with fronto-temporal dementia
Eligibility
Sex/Gender
ALL
Age
45 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* haven given written consent Participants with psychiatric conditions: * Schizophrenia (DSM-V criteria) with or without cognitive involution * Bipolar disorder (DSM-V criteria) with or without cognitive involution Participants with neurodegenerative disease: * probable or definite FTD (Rascovsky criteria 2011) * Biological Alzheimer's disease with typical CSF (NIA-AA 2011)
Exclusion criteria
* Uninterviewable patient and/or missing history * History of recent or previous head trauma with loss of consciousness * History of ischemic or hemorrhagic stroke * Chronic alcoholism / chronic drug use * Progressive somatic pathology / severe metabolic disorder / poorly controlled epilepsy * Age \< 45 years * Age \> 80 years * Electroconvulsive therapy for less than 6 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| neurofilament light chain | two months | serum neurofilament light chain concentration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total tau | two months | serum tau protein concentration |
| GFAP Glial fibrillary acidic protein | two months | Serum GFAP concentration |
| neurofilament heavy chain (pNF-h) | two months | Serum neurofilament heavy chain (pNF-h) concentration |
Countries
France
Contacts
Primary ContactDorey Jean-Michel, MD,PHD
Backup ContactSARTELET lydie
Outcome results
None listed